在喘患者中,VEGF刺激对CD11b受体对外周异osinophils的影响
Krzysztof Gomułka1, Maciej Tota2, Kacper Brzdąk2
1Clinical Department of Internal Medicine, Pneumology and Allergology, Wroclaw Medical University, ul. M. Curie-Skłodowskiej 66, 50-369 Wrocław, Poland.
International journal of molecular sciences
|May 27, 2023
概括
血管内皮生长因子 (VEGF) 增强了喘患者的乙素活性,增加了CD11b的表达. 这表明VEGF在喘病原和氨酸细胞信号传递中起着重要作用.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 分子生物学分子生物学
背景情况:
- 喘是一种复杂的呼吸系统疾病,其特点是气道炎症和过度反应.
- 诸如血管内皮生长因子 (VEGF) 之类的埃索诺菲尔和细胞因子都与喘的发病有关.
- 对于喘研究来说,了解氨基酸激活标志物至关重要.
研究的目的:
- 在喘患者中研究CD11b激活标志物的表达在周围乙氨基酸上.
- 为了评估VEGF刺激对eosinophil CD11b表达 in vitro的影响.
- 探索VEGF诱导的CD11b表达与喘中呼吸道狭窄的严重程度之间的关系.
主要方法:
- 使用流细胞计测量,测量了外周血液中埃索诺菲尔的CD11b表达.
- 研究对象包括78名喘患者 (可逆和不可逆的支气管收缩) 和40名健康对照.
- 用VEGF (250 ng/mL和500 ng/mL) 或fMLP (阳性对照) 刺激了埃索诺菲尔.
主要成果:
- 喘患者的基底CD11b表达在未受刺激的乙氨基酸上略有升高,特别是那些有不可逆转缩小的患者.
- 与健康对照人群相比,VEGF刺激显著增加了喘患者在乙氨基酸上的CD11b表达 (p <0.05).
- 由VEGF诱导的CD11b表达独立于VEGF度和气道狭窄程度.
结论:
- 在喘患者中,VEGF增强了外围乙氨基基基活性,并诱导了CD11b的表达.
- 在喘中,VEGF可能在乙氨基基原始化和CD11b介导的信号传递中发挥着被低估的作用.
- 这些发现突出了喘管理的潜在治疗目标.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
361
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
361
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
01:20Asthma: Pathogenesis and Management
467
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
467
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
319
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
319
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:19Antiasthma Drugs: Leukotriene Modifiers
379
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
379